Figure 7

PCA inhibits ASFV replication by targeting various stages of the ASFV life cycle. A Schematic illustration of the time-of-addition experiment. B Effects of eight PCA treatments on the Gluc activities of rASFV-Gluc/EGFP. At 24 hpi, the supernatants were collected to detect Gluc activities, and the inhibitory effects of PCA were analysed, with DMSO serving as the negative control. C and D Comparison of the anti-ASFV inhibitory effects of PCA to those of other anti-ASFV molecules. PAMs were infected with rASFV-Gluc/EGFP (MOI = 0.2) and treated with 10 μM PCA, berbamine dihydrochloride (BAD), berbamine (BA), or gamithromycin (GAM). At 36 hpi, the supernatants from the PAMs were collected to detect Gluc activities (C), and the ASFV genome copies were detected by qPCR (D) to compare the inhibitory effects of PCA with those of other compounds. **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.